We are live on ! Find out more
BBH icon

VanEck Biotech ETF
BBH

102 hedge funds and large institutions have $121M invested in VanEck Biotech ETF in 2022 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 19 increasing their positions, 30 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more call options, than puts

Call options by funds: $239K | Put options by funds: $211K

1.54% less ownership

Funds ownership: 29.97% → 28.43% (-1.5%)

6% less funds holding

Funds holding: 108 → 102 (-6)

8% less capital invested

Capital invested by funds: $132M → $121M (-$10.2M)

23% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 13

37% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 30

Holders
102
Holders Change
-6
Holders Change %
-5.56%
% of All Funds
1.76%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
19
Reduced
30
Closed
13
Calls
$239K
Puts
$211K
Net Calls
+$28K
Net Calls Change
+$261K

Top Buyers

Rank Fund Capital Flow
1
PGFC
Peapack-Gladstone Financial Corp
New Jersey
+$4.36M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.9M
3
Citadel Advisors
Citadel Advisors
Florida
+$1.79M
4
JMPWA
JP Morgan Private Wealth Advisors
California
+$1.59M
5
LJAC
L.J. Altfest & Co
New York
+$846K

Top Sellers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
-$4.75M
2
CCA
Conservest Capital Advisors
Pennsylvania
-$3.49M
3
Morgan Stanley
Morgan Stanley
New York
-$1.88M
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$1.64M
5
LPL Financial
LPL Financial
California
-$1.51M
Name Holding Trade Value Shares
Change 		Change in
Stake
AF
76
Arrow Financial
New York
$35K – – –
TC
77
Truvestments Capital
Florida
$35K – – –
First Manhattan
78
First Manhattan
New York
$28K – – –
AIM
79
Anchor Investment Management
South Carolina
$23.2K – – –
US Bancorp
80
US Bancorp
Minnesota
$21K – – –
EDRH
81
Edmond de Rothschild Holding
Switzerland
$18K – – –
AF
82
Allworth Financial
California
$17K – – –
EIP
83
Ellis Investment Partners
Pennsylvania
$15K -$36.3K -240 -68%
CG
84
Cutler Group
California
$14K -$60.5K -400 -80%
FCMT
85
Founders Capital Management (Texas)
Texas
$14K – – –
WT
86
Whittier Trust
California
$14K – – –
FP
87
Financial Perspectives
Minnesota
$12.4K – – –
LFASL
88
Lugano Financial Advisors SA (LFA)
Switzerland
$11K -$19.1K -126 -63%
HWM
89
HighMark Wealth Management
Minnesota
$11K – – –
National Bank of Canada
90
National Bank of Canada
Quebec, Canada
$11K – – –
HI
91
Harbour Investments
Wisconsin
$9K – – –
Citigroup
92
Citigroup
New York
$7K – – –
RIA
93
Realta Investment Advisors
Delaware
$7K +$7.56K +50 New
GFPC
94
Global Financial Private Client
Florida
$6.31K – – –
Fidelity Investments
95
Fidelity Investments
Massachusetts
$5K -$302 -2 -6%
CPA
96
Cardiff Park Advisors
California
$5K +$5.29K +35 New
PP
97
Pacifica Partners
Canada
$4K – – –
AIP
98
Ameritas Investment Partners
Nebraska
$4K +$1.51K +10 +50%
CFGS
99
Concourse Financial Group Securities
Alabama
$3K – – –
VanEck Associates
100
VanEck Associates
New York
$3K – – –
1 2 3
4
5

BBH Hedge Fund Activity: Q3 2022 in Review

102 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q3 2022, worth a combined $121M — down 7.8% from $132M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of BBH and 10 opened new positions — a net loss of 3 holders — while 30 trimmed existing stakes and 19 added.

The largest buyer was Peapack-Gladstone Financial Corp, opening a new position worth an estimated $4.36M. The largest seller was Bank of America, cutting an estimated $4.75M.

  • 102 institutional investors held VanEck Biotech ETF (BBH) as of Q3 2022, down from 108 in Q2 2022.
  • Funds reported $121M of VanEck Biotech ETF stock for Q3 2022, down 7.8% quarter-over-quarter.
  • 10 funds opened new VanEck Biotech ETF positions in Q3 2022 and 13 closed out, a net change of -3 holders.
  • The largest VanEck Biotech ETF buyer in Q3 2022 was Peapack-Gladstone Financial Corp, an estimated $4.36M added.
  • The largest VanEck Biotech ETF seller in Q3 2022 was Bank of America, an estimated $4.75M sold.

Based on aggregated 13F filings for Q3 2022.